Edwards Lifesciences Q3 2025 Earnings Report

Edwards Lifesciences EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.59
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Edwards Lifesciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.49 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Edwards Lifesciences Announcement Details

• Quarter: Q3 2025
• Date: 10/23/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 23, 2025
• Conference Call Time: 5:30PM ET

Edwards Lifesciences (NYSE:EW) is a global leader in the development and commercialization of heart valve therapies and critical care monitoring. The company’s core product offerings include transcatheter and surgical heart valves used to treat a variety of valvular heart diseases, as well as systems for hemodynamic monitoring that help guide patient care in intensive care units and operating rooms. Edwards Lifesciences is particularly known for its innovations in transcatheter aortic valve replacement (TAVR) technologies, which have transformed the treatment landscape for patients with severe aortic stenosis.

Founded in 1958 as a division of Baxter International, Edwards Lifesciences pioneered the first commercially available tissue heart valve in the 1960s. The company became a standalone public entity in 2000 and has since expanded its research and development efforts to address a broader range of structural heart and critical care challenges. Edwards maintains a robust pipeline of next-generation devices and collaborates with leading academic and clinical institutions to advance minimally invasive treatment options.

Headquartered in Irvine, California, Edwards Lifesciences serves healthcare providers and patients in more than 100 countries. The company operates manufacturing facilities and research sites across North America, Europe, Asia Pacific and Latin America. With a commitment to clinical education and patient access programs, Edwards works closely with interventional cardiologists, cardiac surgeons and critical care practitioners worldwide to improve procedural outcomes and long-term patient health.

Under the leadership of Chairman and Chief Executive Officer Michael A. Mussallem, Edwards Lifesciences employs over 16,000 people dedicated to advancing cardiovascular therapy and critical care monitoring. The company’s focus on innovation, quality and clinical evidence has positioned it as a trusted partner in the global effort to address unmet needs in structural heart disease and critical care medicine.